PD-1Ab21-BCMACAR-T (CD biopharma)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NamePD-1Ab21-BCMACAR-T (CD biopharma)
Drug Alias NameCD-003CD-203
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCD (Suzhou) Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPla General HospitalCD (Suzhou) Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A